회사 개요
Jyong Biotech Ltd. operates as a science-driven biotechnology entity dedicated to the development and commercialization of plant-derived pharmaceuticals specifically designed for the treatment of urinary system diseases across the United States, the European Union, and Asia markets. The company focuses its research and development efforts on MCS-2, a therapeutic agent formulated for the management of benign prostate hyperplasia and lower urinary tract symptoms. This enterprise is classified within the Healthcare sector and functions specifically in the Biotechnology industry, a domain characterized by high R&D investment cycles and regulatory-intensive product launches. With a reported market capitalization of $203.75M, the company represents a mid-cap biopharmaceutical player, though its annual revenue and total employee count are not disclosed in the available public data. The absence of reported revenue and employee figures suggests that the company is likely in a stage where capital is being prioritized for product development and clinical trials rather than established commercial scale operations typical of mature industry peers.
재무 건전성
The company reported a net income of $-2,945,000 over the trailing twelve months, while its EBITDA stands at $-1,803,000, indicating a significant net loss that exceeds the operating cash loss. The revenue figure for the trailing twelve months is not available in the current financial disclosures, which complicates a direct analysis of the gross margin, though the reported gross margin is explicitly 0.0%. Similarly, the operating margin and profit margin are both recorded at 0.0%, suggesting that the company has not yet generated positive operating profits or that the accounting structure results in zero margins prior to commercial scaling. The firm holds a cash balance of $17.01M against a total debt obligation of $35.19M, resulting in a debt-to-equity metric that is not calculable from the provided data points. This capital structure indicates that the company is currently leveraged, with debt obligations exceeding its liquid cash reserves, which is common for biotechnology firms in the pre-revenue or early commercialization phases. The current ratio is recorded at 0.62, a figure below 1.0 that indicates the company possesses fewer current assets than current liabilities, signaling potential short-term liquidity constraints. Furthermore, the return on equity is not available, whereas the return on assets is -5.4%, revealing that the company's asset base is currently generating a negative return on investment.
밸류에이션 평가
The trailing twelve months P/E ratio and forward P/E ratio are both listed as N/A due to the company's negative earnings position, meaning traditional earnings-based valuation multiples are not applicable at this stage. The price-to-book ratio is recorded at -8.56, a negative value that indicates the market capitalization is significantly below the company's book value, reflecting the high risk associated with unproven assets and negative equity. The price-to-sales ratio is not available, and the EV/EBITDA multiple stands at -116.75, which is a negative metric resulting from the combination of negative EBITDA and the company's market valuation. The stock has exhibited substantial volatility, trading with a 52-week high of $67.00 and a 52-week low of $1.43. Without a specific current share price provided in the facts to calculate the exact percentage difference, the price range indicates a wide trading band where the current market price could be situated anywhere between these extremes, reflecting the high beta environment typical of small-cap biotech stocks. The beta value is not available in the dataset, so a direct comparison of price volatility relative to the broader market cannot be quantified using the provided numbers.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both reported as N/A, preventing a calculation of whether earnings are growing faster or slower than revenue. Consequently, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that the company does not distribute dividends to shareholders. Given the negative net income and lack of earnings, the company is not in a position to sustain a dividend payout, and instead, it must reinvest any available cash flow or raise capital to fund its research and development activities for MCS-2. The overall growth and income profile is characterized by a lack of historical earnings growth data and a zero dividend yield, consistent with the operational reality of a biotechnology company focused on commercializing a single therapeutic agent for urinary system diseases.